Israel - English - Ministry of Health

inovamed ltd - pioglitazone as hydrochloride - tablets - pioglitazone as hydrochloride 15 mg - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

Israel - English - Ministry of Health

inovamed ltd - pioglitazone as hydrochloride - tablets - pioglitazone as hydrochloride 30 mg - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance .

Israel - English - Ministry of Health

inovamed ltd - pioglitazone as hydrochloride - tablets - pioglitazone as hydrochloride 45 mg - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance .

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pioglitazone hydrochloride, quantity: 33.069 mg (equivalent: pioglitazone, qty 30 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; hyprolose; magnesium stearate; carmellose calcium - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise:,as monotherapy,as dual therapy to improve glycaemic control,- in combination with metformin or sulfonylurea,- in combination with insulin,as triple therapy to improve glycaemic control,- in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pioglitazone hydrochloride, quantity: 49.604 mg (equivalent: pioglitazone, qty 45 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; hyprolose; lactose monohydrate; carmellose calcium - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise:,as monotherapy,as dual therapy to improve glycaemic control,- in combination with metformin or sulfonylurea,- in combination with insulin,as triple therapy to improve glycaemic control,- in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pioglitazone hydrochloride, quantity: 16.535 mg (equivalent: pioglitazone, qty 15 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise:,as monotherapy,as dual therapy to improve glycaemic control,- in combination with metformin or sulfonylurea,- in combination with insulin,as triple therapy to improve glycaemic control,- in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pioglitazone hydrochloride, quantity: 49.605 mg - tablet, uncoated - excipient ingredients: carmellose calcium; hyprolose; lactose monohydrate; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pioglitazone hydrochloride, quantity: 16.535 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; carmellose calcium; magnesium stearate; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pioglitazone hydrochloride, quantity: 33.07 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; carmellose calcium; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Canada - English - Health Canada

ratiopharm inc division of teva canada limited - pioglitazone (pioglitazone hydrochloride) - tablet - 15mg - pioglitazone (pioglitazone hydrochloride) 15mg - thiazolidinediones